For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Among the eight people who Robert F. Kennedy Jr. announced would make up his new group of outside vaccine advisers to the US Centers for Disease Control and Prevention are an emergency physician who ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

( The Hill) — The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

The U.S. Food and Drug Administration has approved Moderna’s (MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 ...